Shares of Natco Pharma Ltd were trading in the red and 2% lower on 13 February after the company announced that the US drug authority had issued seven Form 483 observations for the company’s Chennai API unit.
The business stated in an exchange filing that the US Food and Drug Administration (USFDA) issued these observations following an inspection of the active pharmaceutical ingredient (API) division facility in Manali, Chennai, from 17 November to 21 November, 2025.
Natco Pharma stated that the USFDA issued the establishment inspection report (EIR), which classified the inspection as voluntary action indicated (VAI).
This development comes just one day after the company’s results were released. The combined net profit climbed by 14.3% to Rs 152 crore from Rs 133 crore in the same period last year.
Its revenue rose 36.3% to 647.3 crore from 474.8 crore the previous year. The company generated EBITDA of 158.7 crore, up from 39 crore in the prior year. Its EBITDA margin increased from 8.2% last year to 24.5% this year.
At .11:55 am, the shares of Natco Pharma were trading 1.63% lower at Rs 826.20 on NSE.
The future of investing is here!
Tradz by EquityPandit leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app todayand 10x your trading & investing journey!
Click here to check market prediction for next trading session.
